Daily BriefsHealthcare

Daily Brief Health Care: Taisho Pharmaceutical Holdin, New Horizon Health and more

In today’s briefing:

  • Taisho Pharma (4581 JP) – Japan’s Newest Biggest MBO; The Price Is Light!
  • Taisho Pharmaceutical (4581 JP): MBO Tender Offer at JPY8,620
  • 2024 High Conviction – New Horizon Health – Overhangs Are Over, Upgraded ’23 Guidance


Taisho Pharma (4581 JP) – Japan’s Newest Biggest MBO; The Price Is Light!

By Travis Lundy

  • Just past the 22-year anniversary of the deal-break from a previous takeover involving the large OTC drug firm, Taisho Pharmaceutical Holdin (4581 JP) announced an MBO Takeover for the company.
  • Set at a 55.5% premium, it is not particularly surprising as a deal. The family is rolling in their interests. It looks like estate planning. The Board supports and recommends. 
  • Unfortunately, like many recent MBOs, this one is light at 0.85 book where net cash, securities, and net receivables and inventory make up 68% of the takeover price. 

Taisho Pharmaceutical (4581 JP): MBO Tender Offer at JPY8,620

By Arun George

  • Taisho Pharmaceutical Holdin (4581 JP) has recommended an MBO tender offer of JPY8,620 per share, a 55.5% premium to the undisturbed (24 November). 
  • The transaction is a two-step acquisition through a cash tender offer and subsequent squeeze-out. The lower limit of the tender offer is set at a 66.67% ownership ratio.
  • Irrevocables represent a 40.31% ownership ratio. The minimum acceptance condition requires a 44% minority acceptance rate. The offer is attractive vs. historical and peer multiples.

2024 High Conviction – New Horizon Health – Overhangs Are Over, Upgraded ’23 Guidance

By Ke Yan, CFA, FRM

  • New Horizon reported a strong 1H2023 results. Company has upgraded its ’23 sales guidance.
  • The company will continue to deliver strong sales growth despite recent anti-corruption movement in China.
  • We believe that the evidence presented by the recent short-selling report is not sound. We believe the impact is over. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars